阿奇霉素肠溶胶囊与红霉素肠溶胶囊用于咳嗽变异性哮喘合并肺炎支原体感染患儿的疗效及安全性比较  

Comparison on Clinical Efficacy and Safety of Azithromycin and Erythromycin Enteric-Coated Capsules in Children with Cough Variant Asthma Complicated with Mycoplasma Pneumoniae Infection

作　　者：谢志超[1] 邸晓华[1] 罗丽娇[1] 袁慧珍[1] XIE Zhichao;DI Xiaohua;LUO Lijiao;YUAN Huizhen(Dept. of Pediatrics, Dongguan People's Hospital, Guangdong Dongguan 523059, China)

机构地区：[1]东莞市人民医院儿科

出　　处：《中国医院用药评价与分析》2019年第8期940-942,共3页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：广东省东莞市社会科技发展(重点)项目(No.2018507150011654)

摘　　要：目的:比较阿奇霉素肠溶胶囊与红霉素肠溶胶囊用于咳嗽变异性哮喘合并肺炎支原体(mycoplasma pneumoniae,MP)感染患儿的疗效及安全性。方法:选取2016年11月至2018年10月东莞市人民医院收治的咳嗽变异性哮喘合并MP感染患儿110例,根据诊治时间进行排序,奇数为观察组,偶数为对照组,每组55例。对照组患儿给予常规治疗+红霉素肠溶胶囊治疗,观察组患儿给予常规治疗+阿奇霉素肠溶胶囊治疗。观察两组患儿的症状改善情况、炎性因子水平、临床疗效和不良反应发生情况。结果:治疗后,观察组患儿的症状评分、睡眠质量评分明显优于对照组,差异均有统计学意义(P<0.05);观察组患儿IL-2、IL-4及IL-10水平明显优于对照组,差异均有统计学意义(P<0.05);观察组患儿的总有效率为89.1%(49/55),明显高于对照组的70.9%(39/55),差异有统计学意义(P<0.05)。观察组、对照组患儿的不良反应发生率分别为16.4%(9/55)、18.2%(10/55),差异无统计学意义(P>0.05)。结论:阿奇霉素肠溶胶囊与红霉素肠溶胶囊对小儿咳嗽变异性哮喘合并MP感染均有一定效果,且安全性相近,但阿奇霉素肠溶胶囊在抑制炎症方面更具优势。OBJECTIVE: To compare the efficacy and safety of azithromycin and erythromycin enteric-coated capsules in children with cough variant asthma complicated with Mycoplasma pneumoniae(MP) infection. METHODS: Totally 110 children with cough variant asthma complicated with MP infection admitted into Dongguan People’s Hospital from Nov. 2016 to Oct. 2018 were extracted. According to the time of diagnosis and treatment, the odd number was the observation group, the even number was the control group, with 55 cases in each group. Patients in the control group were treated with conventional treatment + Erythromycin enteric-coated capsules, and the observation group were given conventional treatment + Azithromycin enteric-coated capsules. The improvement of symptoms, inflammatory factor levels, clinical efficacy and adverse drug reactions of two groups were observed. RESULTS: After treatment, the symptom score and sleep quality score of the observation group were significantly better than those of the control group, the differences were statistically significant(P<0.05);the levels of IL-2, IL-4 and IL-10 in the observation group were significantly better than those in the control group, the differences were statistically significant(P<0.05);the total effective rate of the observation group was 89.1%(49/55), significantly higher than that of the control group [70.9%(39/55)], the difference was statistically significant(P<0.05). The incidence of adverse drug reactions in the observation group and control group was respectively 16.4%(9/55) and 18.2%(10/55), with no statistically significant difference(P>0.05). CONCLUSIONS: Azithromycin enteric-coated capsules and erythromycin enteric-coated capsules have certain effects on children with cough variant asthma and MP infection, and the safety is similar, yet azithromycin enteric-coated capsules have more advantages in inhibiting inflammation in children.

关 键 词：阿奇霉素 红霉素肠溶胶囊 咳嗽变异性哮喘 肺炎支原体感染 儿童 

分 类 号：R978.1[医药卫生—药品]